Literature DB >> 17164028

What is a mood stabilizer?

Guy M Goodwin1, Gin S Malhi.   

Abstract

The concept of mood stability is attractive to both patients and clinicians alike, and hence the term 'mood stabilizer' has widespread currency. However, its worldwide acceptance and use in clinical practice is at odds with the absence of official recognition by regulatory authorities. The ideal mood stabilizer is said to have efficacy in the treatment of acute manic and depressive episodes, and also be effective in the prevention of recurrences. However, in reality, few drugs with perhaps the exception of lithium, come close to this gold standard; yet many agents aspire to the title, and some have arguably achieved it prematurely. It is, therefore, important to reconsider the definition of a mood stabilizer and critically review which agents, if any, satisfy the necessary eligibility requirements by reference to reasonable criteria and comparator data. The term mood stabilizer is an important label. It needs to be applied judiciously because it confers clinical credibility and qualifies long-term use in maintenance and prophylaxis. It is also important with respect to developing guidelines for treatment and the further development of novel agents. Most importantly, however, it is a term that is innately appealing because of what it promises: for this reason alone it should encompass only those agents that can deliver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164028     DOI: 10.1017/S0033291706009305

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  7 in total

1.  Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction.

Authors:  Camila Nascimento; Helena Kyunghee Kim; L Trevor Young; Karina Martinez Mendonça; Lea Tenenholz Grinberg; Beny Lafer; Ana Cristina Andreazza
Journal:  J Neural Transm (Vienna)       Date:  2014-09-27       Impact factor: 3.575

2.  [Are atypical antipsychotic drugs the first line treatment for bipolar disorders? Against].

Authors:  B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

Review 3.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 4.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

5.  Lithium and the risk of chronic kidney disease: A population-based case-control study.

Authors:  Mikkel Højlund; Jane Sterndorff Winkel; Mads Nybo; Jesper Hallas; Daniel Pilsgaard Henriksen; Per Damkier
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-06-06       Impact factor: 3.688

6.  Quetiapine monotherapy for bipolar depression.

Authors:  Michael E Thase
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

7.  Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review.

Authors:  Manuel Gardea-Resendez; Mehmet Utku Kucuker; Caren J Blacker; Ada M-C Ho; Paul E Croarkin; Mark A Frye; Marin Veldic
Journal:  Front Pharmacol       Date:  2020-04-22       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.